Enrolling Clinical Studies
ANXIETY DISORDER (PRIMARY/GENERALIZED)
This study will evaluate the efficacy, safety and tolerability of an oral medication (ITI-1284) as a complementary treatment in patients with Generalized Anxiety Disorder.
Requirements:
• Men or women over 18 years old.
• Meet diagnostic criteria for moderate or severe Generalized Anxiety Disorder.
• Have a history of inadequate response for at least 1 GAD treatment (E.g., Duloxetine, Paroxetine, Buspirone, Venlafaxine, Escitalopram) in the last 6 weeks.
• Subject must have copy of recent pharmacy record or medical record.
• No history of other psychiatric disorders: major depression, schizophrenia, psychosis, bipolar.
• No history of severe alcohol abuse, drug abuse or any suicidal ideation.
• Not being taking daily psychotropic or non-psychotropic drugs: benzodiazepines, sedative, opioids, mood stabilizers, anxiolytics, anticonvulsants (if so, willing to discontinue).
• No history of receiving Electroconvulsive Therapy (ECT).
• Female participants must not be breast-feeding or pregnant.
• No history of cancer in the last 5 years, gastric bypass, HIV, epilepsy or major health condition
Study Duration:
This study contains a total of 9 visits over a period of 10 weeks.
Compensation:
This study will pay $125 per in-clinic visit.
A total of $1,125 for completing all study’s visits.